DocMorris goes European: new branding for marketplaces in Spain and France
11.2.2021 11:41:32 CET | news aktuell GmbH | Pressemelding
Heerlen/Barcelona, 11.02.2021 – DocMorris is taking the next step in implementing its new brand architecture on the way to becoming the European umbrella brand of the digital healthcare ecosystem of the Zur Rose Group. The successful launch of the new branding for the DocMorris pharmacy and the DocMorris+ healthcare platform in Germany marked just the beginning of a shift of paradigm to digital healthcare. This successful first step in Germany is now followed by PromoFarma, the leading brand for online pharmacy marketplaces in Spain, and DoctiPharma, the second biggest brand in France, who see their brand now linked to the DocMorris brand identity.
The new brand appearance of PromoFarma and DoctiPharma underlines its brand evolutions by using the green heart as a symbol for health. The varying shades of green for the heart represent the variety of current and future health solutions, which can be made even more personal and individual thanks to digitalisation. The light green “by DocMorris” descriptor confirms its link and shows both marketplaces are part of the European healthcare ecosystem.
DocMorris, best known in Germany, has been chosen by the Zur Rose Group as umbrella brand for its European healthcare ecosystem. The international success of the Christmas film “#Herzensangelegenheit” [a matter of the heart] emphasises the strength of the DocMorris brand and how the brand emotionally resonates with consumers across European markets. The cooperation with global healthcare company Novo Nordisk in Germany – with the intention to expand it across Europe – demonstrates how important it is to work with top-class partners in healthcare to bring the ecosystem to life under one single brand. Combining specialist knowledge from partners with consumer reach makes it possible to better enable people to manage their own health and improve their quality of life conveniently and flexibly. Gaining additional marketplace expertise in Spain and France within the healthcare ecosystem increases its attractiveness for consumers allowing for more product accessibility and faster time-to-market. With the ambition to expand further their product offering and providing additional digital services, PromoFarma and DoctiPharma will also benefit from the existing expertise under the DocMorris brand and many years of experience across the Zur Rose Group to make it even simpler for people to access healthcare.
On this basis, the DocMorris healthcare ecosystem will enable people all over Europe to manage their health in one click – safely and easily. The healthcare ecosystem will make it possible for all users, medical specialists, pharmacists and healthcare service providers to experience the vision of seamless and personal 360-degree health journeys.
The European DocMorris branding was developed with the famous international design agency Mucho of Barcelona, Spain.
Kontakter
eHealth ecosystem contact
Betül Susamis Unaran
Chief Strategy and Digital Officer
Email: betul.unaran@zurrose.com
Phone +41 79 834 41 40
Om news aktuell GmbH
news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.
Følg pressemeldinger fra news aktuell GmbH
Registrer deg med din e-postadresse under for å få de nyeste sakene fra news aktuell GmbH på e-post fortløpende. Du kan melde deg av når som helst.
Siste pressemeldinger fra news aktuell GmbH
FEV collaborates with Microsoft on efficient AI model approach for in car applications built on NVIDIA9.7.2026 11:05:00 CEST | Press release
Aachen – FEV is collaborating with Microsoft to integrate powerful, in-vehicle Generative AI capabilities built on NVIDIA GPU-accelerated compute and AI model microservices. The cooperation aims to enable multimodal voice, text, and gesture interactions directly in the vehicle – independent of a permanent Internet connection.
Acrobat Studio og Acrobat KI-assistent: den nye generasjonen KI-støttet produktivitet – nå også på norsk8.7.2026 15:08:48 CEST | Press release
SAN JOSE, Calif. - 8. juli 2026 - Adobe utvider tilgjengeligheten til Acrobat Studio og Acrobat KI-assistenten i Norge. Nå er de KI-støttede funksjonene for produktivitet og kreavtivitet også tilgjengelige på norsk, og kan dermed brukes av brukere på lokalt språk. Acrobat Studio kombinerer Adobe Acrobat Pro, Adobe Express Premium og smarte KI-assistenter. Acrobat KI-assistent er også tilgjengelig som et separat tillegg for alle Adobe Acrobat-produkter (Acrobat Reader, Acrobat Standard og Acrobat Pro) – et fleksibelt alternativ for alle som ønsker å bruke KI-støttede funksjoner kun når de arbeider med dokumenter. Begge disse tilbudene gjør det mulig for brukere å raskere samle inn informasjon i PDF-er og Office-dokumenter, opprette innhold og effektivisere arbeidsflyten. Acrobat Studio og Acrobat KI-assistenten markerer et viktig trinn i utviklingen av PDF-filen, som har blitt standarden for viktige dokumenter siden den ble lansert av Adobe i 1993. Acrobat utvikler seg fra et ledende pr
Grünenthal receives FDA Orphan Drug and Rare Pediatric Disease Designations for Tegacorat for the Treatment of Duchenne Muscular Dystrophy8.7.2026 10:37:04 CEST | Press release
Aachen, 08 July 2026 – Grünenthal announced today that its investigational compound tegacorat (GRM-01) received Orphan Drug and Rare Pediatric Disease Designations from the US Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy (DMD).
Grünenthal successfully completes Phase I trial with Nociceptin Receptor (NOP) Agonist29.6.2026 12:28:23 CEST | Press release
The investigational compound has a unique mechanism of action and the potential to become a first-in-class therapy option for the treatment of acute and chronic pain. In a Phase I trial, the investigational compound was demonstrated to be safe and well tolerated. A Phase II trial will commence later this year.
FRITZ: YouGov survey in 14 countries: Trust in router manufacturers from different regions European consumers mistrust Chinese routers29.6.2026 10:00:00 CEST | Press release
More than half of consumers in Norway mistrust routers from Chinese manufacturers (59%) Many mistrust devices made in the USA European routers enjoy a high level of trust across Europe (60%) For half of Europeans (55%), the ‘Made in Europe’ label important to when making a purchase
I vårt presserom finner du alle våre siste pressemeldinger, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.
Besøk vårt presserom

